Gsk PLC (GSK) — 6-K Filings

All 6-K filings from Gsk PLC. Browse 32 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (32)

GSK plc Files Director/PDMR Shareholding Report — Apr 20, 2026 Risk: low
On April 20, 2026, GSK plc filed a Form 6-K, reporting a Director/PDMR Shareholding. The filing includes details about shareholdings of directors and persons di
GSK's BLENREP Approved in China for Multiple Myeloma — Apr 20, 2026 Risk: low
GSK plc announced on April 20, 2026, that its drug BLENREP has been approved in China for the treatment of relapsed or refractory multiple myeloma in adults who
GSK plc Files Share Transaction Report (6-K) — Apr 20, 2026 Risk: low
On April 20, 2026, GSK plc filed a Form 6-K with the SEC, reporting a transaction involving its own shares. The filing, with SEC Accession No. 0001654954-26-003
GSK plc Files 6-K on Share Transaction — Apr 17, 2026 Risk: low
GSK plc filed a Form 6-K on April 17, 2026, reporting a transaction in its own shares. The filing details a transaction involving GSK plc's own shares, with the
6-K Filing — Apr 16, 2026
6-K Filing — Apr 16, 2026
GSK plc Completes Acquisition of 35Pharma Inc. — Apr 15, 2026 Risk: low
GSK plc announced on April 15, 2026, the completion of its acquisition of 35Pharma Inc. The filing is a Form 6-K, reporting this significant corporate event for
6-K Filing — Apr 15, 2026
6-K Filing — Apr 14, 2026
6-K Filing — Apr 13, 2026
GSK plc Files Form 6-K on Share Transactions — Apr 13, 2026 Risk: low
On April 13, 2026, GSK plc filed a Form 6-K with the SEC, reporting a transaction involving its own shares. The filing, with SEC Accession No. 0001654954-26-003
GSK plc Files Director Shareholding Report — Apr 10, 2026 Risk: low
On April 10, 2026, GSK plc filed a Form 6-K, reporting a Director/PDMR Shareholding. The filing details share transactions by individuals who are directors or P
GSK plc Reports Share Transaction in 6-K Filing — Apr 10, 2026 Risk: low
On April 10, 2026, GSK plc filed a Form 6-K with the SEC, reporting a transaction involving its own shares. The filing details a transaction in its own shares,
GSK plc Files Director/PDMR Shareholding Report — Apr 9, 2026 Risk: low
On April 9, 2026, GSK plc filed a Form 6-K with the SEC, reporting a Director/PDMR Shareholding. The filing details transactions related to director and PDMR (P
6-K Filing — Apr 9, 2026
GSK plc Announces EXDENSUR Approval in China — Apr 8, 2026 Risk: low
GSK plc filed a Form 6-K on April 8, 2026, reporting an approved EXDENSUR for use in China. The filing includes the complete submission text file and details GS
6-K Filing — Apr 8, 2026
GSK plc Files 6-K on Share Transaction — Apr 7, 2026 Risk: low
GSK plc filed a Form 6-K on April 7, 2026, reporting a transaction in its own shares. The filing details a transaction involving GSK plc's own shares, with the
6-K Filing — Apr 2, 2026
6-K Filing — Apr 1, 2026
GSK plc Files Share Transaction Report (6-K) — Apr 1, 2026 Risk: low
GSK plc filed a Form 6-K on April 1, 2026, reporting a transaction involving its own shares. The filing, submitted on a.htm, details activities related to GSK's
6-K Filing — Apr 1, 2026
6-K Filing — Mar 31, 2026
GSK's Bepirovirsen Accepted for Review in China — Mar 30, 2026 Risk: low
GSK plc announced on March 30, 2026, that their investigational drug, bepirovirsen, has been accepted for review by China's National Medical Products Administra
GSK's TRELEGY ELLIPTA approved for severe asthma in China — Mar 30, 2026 Risk: low
GSK plc announced on March 30, 2026, that its treatment for severe asthma, 'TRELEGY ELLIPTA', has been approved in China. This approval is based on positive res
GSK plc Files 6-K on Share Transaction — Mar 30, 2026 Risk: low
On March 30, 2026, GSK plc filed a Form 6-K with the SEC, reporting a transaction involving its own shares. The filing, with SEC Accession No. 0001654954-26-002
6-K Filing — Mar 27, 2026
GSK's Bepirovirsen Accepted for EMA Review — Mar 27, 2026 Risk: low
GSK plc announced on March 27, 2026, that their submission for Bepirovirsen has been accepted for review by the European Medicines Agency (EMA). This acceptance
GSK Files 6-K on Own Share Transactions — Mar 26, 2026
GSK plc filed a 6-K on March 26, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r
GSK plc Files 6-K for Annual General Meeting Notice — Mar 25, 2026
GSK plc, a pharmaceutical giant, filed a 6-K on March 25, 2026, to announce its Notice of Annual General Meeting (AGM). This filing, identified by accession num
GSK plc Reports Transaction in Own Shares on March 25, 2026 — Mar 25, 2026
GSK plc filed a 6-K on March 25, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r
GSK Reports Own Share Transaction on March 24, 2026 — Mar 24, 2026
GSK plc filed a 6-K on March 24, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX